The Centers for Medicare & Medicaid Services granted Medicare coverage for Personalis’ NeXT Personal molecular residual disease (MRD) test to support surveillance of stages I–III non‑small cell lung cancer. The decision follows clinical performance data generated in partnership with the TRACERx consortium and published validation work in Nature Medicine. Personalis said coverage broadens patient access to whole‑genome sequencing–based MRD surveillance and will be a commercial catalyst for adoption. MRD tests detect low‑level tumor DNA in blood after treatment and are used to identify recurrence earlier than imaging; the test’s sensitivity derives from tumor‑informed whole‑genome approaches tracking hundreds to thousands of patient‑specific mutations.